(19)
(11) EP 3 045 176 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
12.12.2018 Bulletin 2018/50

(45) Mention of the grant of the patent:
07.11.2018 Bulletin 2018/45

(21) Application number: 15199540.4

(22) Date of filing: 03.09.2004
(51) International Patent Classification (IPC): 
A61K 31/445(2006.01)
 C07D 401/04(2006.01)

(54)

POLYMORPHIC FORMS OF 3-(4-AMINO-1-OXO-1,3 DIHYDROISOINDOL-2-YL)-PIPERIDINE-2,6-DIONE

POLYMORPHE FORMEN VON 3-(4-AMINO-1-OXO-1,3-DIHYDRO-ISOINDOL-2-YL)-PIPERIDIN-2,6-DION

FORMES POLYMORPHES DE 3-(4-AMINO-1-OXO-1,3 DIHYDRO-ISOINDOL-2-YL)-PIPÉRIDINE-2,6-DIONE

(84) Designated Contracting States:
AT BE CH CZ DE DK ES FI FR GR HU IE IT LI LU NL PL PT SE TR

(30) Priority: 04.09.2003 US 499723 P

(43) Date of publication of application:
20.07.2016 Bulletin 2016/29

(62) Application number of the earlier application in accordance with Art. 76 EPC:
11185757.9 / 2425836
04783095.5 / 1667682

(73) Proprietor: Celgene Corporation
Summit, NJ 07901 (US)

(72) Inventors:
  • Chen, Roger, Shen-Chu
    Edison, NJ 08820 (US)
  • Muller, George, W.
    Rancho Santa Fe, CA 92067 (US)
  • Jaworsky, Markian, S.
    Hopewell, NJ 08525-1001 (US)
  • Saindane, Manohar, T.
    Decauer, GA 30033 (US)
  • Cameron, Louise
    Nazareth, PA 18064 (US)

(74) Representative: Jones Day 
Rechtsanwälte, Attorneys-at-Law, Patentanwälte Prinzregentenstrasse 11
80538 München
80538 München (DE)


(56) References cited: : 
US-A1- 2002 045 643
   
  • CORRAL L G ET AL: "IMMUNOMODULATION BY THALIDOMIDE AND THALIDOMIDE ANALOGUES", ANNALS OF THE RHEUMATIC DISEASES, BRITISH MEDICAL ASSOCIATION, LONDON, GB, vol. 58, no. SUPPL. 01, 1 January 1999 (1999-01-01), pages I107-I113, XP000861990, ISSN: 0003-4967
  • LENTZSCH S ET AL: "S-3-amino-phthalimido-glutarimide inhibits angiogenesis and growth of B-cell neoplasias in mice", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 62, 15 April 2002 (2002-04-15), pages 2300-2305, XP002959459, ISSN: 0008-5472
  • CAIRA M R: "CRYSTALLINE POLYMORPHISM OF ORGANIC COMPOUNDS", TOPICS IN CURRENT CHEMISTRY, SPRINGER, BERLIN, DE, vol. 198, 1 January 1998 (1998-01-01), pages 163-208, XP001156954, ISSN: 0340-1022, DOI: 10.1007/3-540-69178-2_5
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).